Home / news / Proofpoint, Inc. (PFPT), Vertex Pharmaceuticals Incorporated (VRTX) Stock Eyes Ahead of Earnings

Proofpoint, Inc. (PFPT), Vertex Pharmaceuticals Incorporated (VRTX) Stock Eyes Ahead of Earnings

collected by :Molly Tony

With both efficacy and importantly safety exceeding expectations, we believe VRTX at a minimum now has a much improved Orkambi.
Following yesterday’s closing bell, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced positive Phase 3 results from two highly anticipated studies evaluating the tezacaftor and ivacaftor (Kalydeco) combo in cystic fibrosis.
Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases.
Out of 14 analysts who cover the stock, 8 suggest a Buy rating and 6 recommend to Hold the stock.
Vertex shares reacted to the news, rising nearly 19% to $16.83.

as informed in

Proofpoint, Inc. (PFPT), Vertex Pharmaceuticals Incorporated (VRTX) Stock Eyes Ahead of Earnings

Proofpoint, Inc. (NASDAQ:PFPT) share price decreased in the last trading session with a previous 52-week high of $88.00.
Presently Proofpoint, Inc. (NASDAQ:PFPT) stock have an ABR of 1.35.
While trading at volume below than average, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) previous 52-week high was $103.73 and moved up 11.10% over the same period, trading at a volume of 1.04 million.
The share price is now up 3.12% for the past three months.
Looking ahead to earnings forecasts, for the running fiscal period, Wall Street analysts have anticipated that the company will report -0.35 earnings per share.

Quarterly EPS Of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) At $0.54

as informed in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) can post EPS of $0.54 when the company releases its quarterly report on 2017-04-26.
For the period settled on 2016-12-31, the Vertex Pharmaceuticals Incorporated reported EPS at $0.13.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has an impact score of 83 and a sentiment score of 0.37.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stock can attain $104.266 target in the approaching year.
On the Zacks strategic scale, the ABR of 2.08 has been set on Vertex Pharmaceuticals Incorporated stock against 2.08 rating in past quarter.

read more
visit us
Markets

Check Also

cheap stocks

Cheap stocks and its trading in financial markets

Cheap stocks, also known as Cent stocks, are ordinary shares of small public companies traded …